Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Sweden-Based Immunovia Locates U.S. Headquarters In Boston, Massachusetts

06/30/2017
Sweden-based Immunovia plans to locate its United States headquarters in Boston, Massachusetts. The facility will design a test for early detection of pancreatic cancer.

This new Immunovia complex will accommodate a CLIA accredited reference laboratory for the Eastern USA as well as facilities for commercialization, covering marketing, sales and customer support.

A highly skilled team has been recruited to carry out the U.S. market introduction of Immunovia's first test, IMMray PanCan-d, in the second half of 2018, company officials said.

Mats Grahn, CEO Immunovia said, "the market introduction of IMMray PanCan-d, our blood based test for earlier detection of pancreas cancer, is the main focus for Immunovia.”

“ We have therefore chosen to establish our USA operations headquarters in Boston, which is the major biotech hub in the world,” Grahn said. “ A very experienced laboratory team will be moving into Immunovia´s own reference laboratory that will cover Eastern USA, adding to our commercial group that will also be located at the Boston facilities. This East coast laboratory complements the existing collaboration we have with Knight Diagnostic Laboratories in Portland, serving Western USA."

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden.

According to company officials, the company is now performing clinical validation studies for the commercialization of IMMray PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer.

Exclusive Research